Genmab Expands SeaGen Alliance

4/19/11Follow @xconomy

Genmab, the Denmark-based developer of antibody drugs, said today it has formed  a second collaboration to use technology from Seattle Genetics (NASDAQ: SGEN) that’s designed to make antibodies more potent. Genmab will seek use the “empowered antibody” technology against a target known as CD74, which is found on various blood cancer and solid tumor cells. Seattle Genetics is getting an undisclosed upfront payment, and will have the right to co-develop and co-market the drug candidate after Genmab completes the first phase of clinical trials.

By posting a comment, you agree to our terms and conditions.